98%
921
2 minutes
20
Purpose: In this study, we evaluated the presence of tau deposition and protein expression of Reelin/GSK-3β/p-Tau signaling pathway in the hippocampus of patients with temporal lobe epilepsy (TLE).
Methods: A total of 37 cases of TLE with and without hippocampal sclerosis (HS) were selected histopathologically for our study with 5 autopsy cases as the control group. Immunohistochemistry and the histelide assay, a novel technique quantifying antigens in paraffin section, were used to confirm the distribution of protein within Reelin/GSK-3β/p-Tau signaling pathway and validate the expression of GSK-3β and AT8 (hyperphosphorylated tau) in this study.
Results: Immunohistochemical staining for AT8 revealed punctate and filamentous positive expression in the CA1, CA2 and CA3 regions of the hippocampus with TLE under the ependyma, distributed in a band-like pattern. By contrast, the control group did not exhibit any immunopositivity. GSK-3β was strongly positive in the neuronal bodies, apical dendrites and axons in both groups of TLE, while all controls were negative. In addition, there was no significant difference in the immunohistochemical labelling of Reelin among all cases. The histelide assay indicated that the amounts of AT8 and GSK-3β were significantly increased in the two TLE groups (P < 0.05). Notably, there was a positive correlation between AT8 and GSK-3β in TLE without HS (P < 0.05).
Conclusion: The present data indicates that phosphorylated tau protein and GSK-3β are activated in the hippocampus of patients with TLE, and this is the first study to examine relevant proteins with the histelide assay in paraffin samples of human tissue. We consider that the regulatory network of tau protein between the two groups may be similar but not identical.
Significance: This study emphasized the Reelin/GSK-3β/p-Tau signaling pathway in TLE with a quantitative data of human tissues innovatively, revealing inspiration for mechanism exploration.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880680 | PMC |
http://dx.doi.org/10.2147/NDT.S495339 | DOI Listing |
Neuropsychiatr Dis Treat
February 2025
Department of Pathology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, People's Republic of China.
Purpose: In this study, we evaluated the presence of tau deposition and protein expression of Reelin/GSK-3β/p-Tau signaling pathway in the hippocampus of patients with temporal lobe epilepsy (TLE).
Methods: A total of 37 cases of TLE with and without hippocampal sclerosis (HS) were selected histopathologically for our study with 5 autopsy cases as the control group. Immunohistochemistry and the histelide assay, a novel technique quantifying antigens in paraffin section, were used to confirm the distribution of protein within Reelin/GSK-3β/p-Tau signaling pathway and validate the expression of GSK-3β and AT8 (hyperphosphorylated tau) in this study.
J Alzheimers Dis
March 2016
Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, Sant Joan d'Alacant, Spain.
In the continuing search for proteins that play a role in Alzheimer's disease (AD) and that are related to the pathological hallmarks, those that influence cognitive function and that constitute potential therapeutic targets deserve special interest. Reelin is a signaling protein that is involved in a cascade of cytoplasmic events that control tau phosphorylation and that regulate synaptic neurotransmission, plasticity, and memory. Both Reelin expression and glycosylation are modulated by amyloid-β (Aβ), suggesting that the activity of Reelin could be affected in AD and hence, its possible influence on this pathology should be taken into consideration.
View Article and Find Full Text PDF